Evaluations of substrate specificity and inhibition at PR/p3 cleavage site of HTLV-1 protease

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 14, 2006, Pages 3761-3764

  Naka, Hiromi ^a   Teruya, Kenta ^a   Bang, Jeong Kyu ^a   Aimoto, Saburo ^a   Tatsumi, Tadashi ^b   Konno, Hiroyuki ^b   Nosaka, Kazuto ^b   Akaji, Kenichi ^b  

^a OSAKA UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

HTLV 1 protease; Hydroxyethylamine dipeptide isostere; Inhibitor; Substrate specificity

Indexed keywords

PROTEINASE; PROTEINASE INHIBITOR;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CARBOXY TERMINAL SEQUENCE; DRUG POTENCY; ENZYME INHIBITION; HUMAN T CELL LEUKEMIA VIRUS 1; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR RECOGNITION; NONHUMAN;

AMINO ACID SEQUENCE; ASPARTIC ENDOPEPTIDASES; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHYLAMINES; HUMANS; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 33746502557     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.04.056     Document Type: Article

References (14)

1. Matsuoka M. Oncogene 22 (2003) 5131
2. Louis J.M., Oroszlan S., and Tözser J. J. Biol. Chem. 274 (1999) 6660
3. Akaji K., Teruya K., and Aimoto S. J. Org. Chem. 68 (2003) 4755
4. Ding Y.S., Rich D.H., and Ikeda R.A. Biochemistry 37 (1998) 17514
5. Tözser J., Zahuczky G., Bagossi P., Louis J.M., Copeland T.D., Oroszlan S., Harrison R.W., and Weber I.T. Eur. J. Biochem. 267 (2000) 6287
6. Kádas J., Weber I.T., Bagossi P., Miklóssy G., Boross P., Oroszland S., and Tözser J. J. Biol. Chem. 279 (2004) 27148
7. Rink H. Tetrahedron Lett. 28 (1987) 3787
8. 6); Pro (2) 2.1, Val (1) 0.97, Ile (2) 2.0, Leu (1) 1.1.
9. Teruya K., Kawakami T., Akaji K., and Aimoto S. Tetrahedron Lett. 43 (2002) 1487
10. 5Na); Pro (1) 0.97, Val (1) 0.96, Ile (1) 0.90, Leu (1) 1.0.
11. Maegawa H., Kimura T., Arii Y., Matsui Y., Kasai S., Hayashi Y., and Kiso Y. Bioorg. Med. Chem. Lett. 14 (2004) 5925
12. 3): δ 0.89 (d, J = 6.6 Hz, 3H), 0.95 (d, J = 6.6 Hz, 3H), 1.22-1.32 (m, 2H), 1.45 (s, 9H), 1.58-1.76 (br m, 2H), 1.80-2.04 (m, 3H), 2.12-2.22 (m, 1H), 2.60-2.73 (m, 3H), 3.09-3.19 (m, 1H), 3.29-3.35 (m, 1H), 3.40-3.52 (br m, 1H), 3.58 (br s, 1H), 3.65 (br s, 1H), 4.62-4.68 (d, J = 5.7 Hz, 2H), 4.73 (br d, J = 9.0 Hz, 1H), 5.20-5.30 (dd, J = 9.3 Hz, J = 1.2 Hz, 1H), 5.30-5.38 (dd, J = 15.7 Hz, J = 1.5 Hz, 1H), 5.88-5.98 (m, 1H). The other intermediates were similarly purified and characterized.
13. Bang J.K., Hasegawa K., Kawakami T., Aimoto S., and Akaji K. Tetrahedron Lett. 45 (2004) 99
14. 3I).